Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
Outline
Claim CME
PDF
Public Health

Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
JAMA
February 15, 2022
Research Letter
Lindsey Wang1;
Pamela B. Davis, MD, PhD2;
David C. Kaelber, MD, PhD, MPH3;
Nora D. Volkow, MD4;
Rong Xu, PhD1
Author Affiliations
  • 1Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • 2Center for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • 3Center for Clinical Informatics Research and Education, MetroHealth System, Cleveland, Ohio
  • 4National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland
Read article on JAMA Network

MOC/CME Information

editorial comment icon
Editorial
Comment
 related articles icon
Related
Articles
 author interview icon
Interviews
 multimedia icon
Multimedia
Read Article Claim CME

Immune responses to mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines decline by 6 months after vaccination,1 although antibody titers are higher with mRNA-1273.1,2 Comparison of vaccinated nonimmunocompromised adults showed lower risk of hospitalization for recipients of mRNA-1273 than BNT162b2 during March-August 2021.3 This study examined breakthrough infections, hospitalizations, and mortality in a general population for these 2 vaccines during the Delta period while considering risk characteristics of vaccine recipients and the varying time since vaccination.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Related Articles

  1. COVID-19 mRNA Vaccines Blunt Breakthrough Infection Severity

  2. Vaccination Doesn’t Eliminate Delta Variant Household Transmission

  3. Vaccine Effectiveness Against COVID-19 and Other Variants of Concern in Utah
    1.00 CME

  4. Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection
    1.00 CME

  5. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by Omicron and Delta Variants
    1.00 CME

  6. Association of Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Predominance
    1.00 CME

See More

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

See More About

Infectious Diseases Vaccination Public Health Coronavirus (COVID-19)
Article Information

Accepted for Publication: January 7, 2022.

Published Online: January 20, 2022. doi:10.1001/jama.2022.0210

Corresponding Author: Rong Xu, PhD, Center for Artificial Intelligence in Drug Discovery, 2103 Cornell Rd, Cleveland, OH 44106 (rxx@case.edu).

Author Contributions: Dr Xu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Davis, Volkow, Xu.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Wang, Volkow, Xu.

Critical revision of the manuscript for important intellectual content: Wang, Davis, Kaelber, Volkow, Xu.

Statistical analysis: Wang.

Obtained funding: Xu.

Administrative, technical, or material support: Davis, Kaelber, Volkow, Xu.

Supervision: Davis, Kaelber, Volkow, Xu.

Conflict of Interest Disclosures: Dr Davis reported receiving grants from the National Institutes of Health outside the submitted work. No other disclosures were reported.

Funding/Support: The study was supported by the National Institute on Alcohol Abuse and Alcoholism (grant R01AA029831), the National Institute on Aging (grants AG057557, AG061388, and AG062272), the National Institute on Drug Abuse (grant UG1DA049435), the National Cancer Institute (grant R25CA221718), and the Clinical and Translational Science Collaborative of Cleveland (grant 1UL1TR002548-01).

Role of the Funder/Sponsor: The study funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

References
1.
Collier  AY , Yu  J , McMahan  K ,  et al.  Differential kinetics of immune responses elicited by Covid-19 vaccines.   N Engl J Med. 2021;385(21):2010-2012. doi:10.1056/NEJMc2115596PubMedGoogle ScholarCrossref
2.
Steensels  D , Pierlet  N , Penders  J , Mesotten  D , Heylen  L .  Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273.   JAMA. 2021;326(15):1533-1535. doi:10.1001/jama.2021.15125PubMedGoogle ScholarCrossref
3.
Self  WH , Tenforde  MW , Rhoads  JP ,  et al; IVY Network.  Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March-August 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(38):1337-1343. doi:10.15585/mmwr.mm7038e1PubMedGoogle ScholarCrossref
4.
Centers for Disease Control and Prevention. COVID Data Tracker variant proportions. Accessed December 8, 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
5.
Centers for Disease Control and Prevention. COVID-19 and people with certain medical conditions. Accessed December 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
6.
Centers for Disease Control and Prevention. Information for clinicians on investigational therapeutics for patients with COVID-19. Accessed December 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
Want full access to the AMA Ed Hub?
Become an AMA member now
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
Become an AMA member now
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Privacy Policy|Terms of Use
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue